BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody.Int J ClinExp Pathol;9(2):1545-1556.Jung YY, Jung WH, Koo JS. BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody. Int J Clin Exp Pathol 2016;9:1545e1556....
Overall, the mutations were prevalent in normal breast and DCs, with 9/9 DCs having measureable levels of at least three of the five mutations.HRASG12D was significantly increased in DCs as compared to normal breast. The most frequent point mutation reported in DC by DNA sequencing,PIK3CAH104...
[22]Yoon JH, Han K, Lee E, et al. Radiomics in predicting mutation status for thyroid cancer: a preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma[J]. PLoS One...
Another arm of the study explored dose limitations of pembrolizumab plus trametinib for patients withBRAFmutation-negative advanced melanoma, although findings have not yet been revealed for this group. Ribas A, Hodi FS, Lawrence DP, et al. Pembrolizumab (pembro) in combination with dabrafeni...
Notably, it has been demonstrated that 13% of BRAF mutations found from 8405 non-small cell lung cancer patients are G469 mutations [23]. Class II mutations exhibit lower ERK phosphorylation activity than BRAF V600E mutation [12]. Class II mutations are mainly located in the activation segment...
21.nik-zainals,vanloop,wedgedc,etal.thelifehistoryof21breastcancers.cell.2012;149(5):994-1007. 22.guoj,sil,kongy,etal.phaseii,open-label,single-armtrialofimatinibmesylateinpatientswithmetastaticmelanomaharboringc-kitmutationoramplification.jclinoncol.2011;29(21):2904-2909. ...
The findings from the ROAR study are also complementary to available case reports supporting the efficacy of dabrafenib plus trametinib in variousBRAFV600Emutation-positive tumors, including breast cancer21, pancreatic cancer22,23, salivary duct cancer24, Bellini duct cancer25, pituitary tumor26, ame...
DetectionofBRAFmutationanditsclinicalsignificanceinthyroidcancer HⅣGJ/e.WUGao— song,MAXiao-peng,LlUran—yan,CHENHua—tao,HUANGWet.DepartmentofBreastandThyroidSur— gery,TongjiHospital,TondiMedicalCollege,HuazhongUniversityofScienceandTechnology,Wuhan ...
BRAF mutations are observed in up to 8% of patients with cancerand are known to behave differently across tumor types.2,3 For example, approximately 50% of patients with melanoma harbor a class I BRAF V600 mutation, whereas approximately 50% to 80% of BRAF mutations in non–small cell l...
【关键词】 BRAF V600E 基因突变; 甲状腺乳头状癌; 细针穿刺细胞学 【中图分类号】 R736.1 【文献标志码】 AThe Clinical Signif i cance of BRAF V600E Mutation in Papillary Thyroid Cancer CHEN Qiang 1,2 , ZHU Jing-qiang 1 .1. Department of Thyroid and Breast Surgery, West China Hospital, ...